Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$7.40 – $30.80
1% from low
Borrow rate
39.02%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $10.1K | $11.4K | $11.4K | $3.3K |
| Gross profit | $0 | $0 | $0 | $0 | −$10.1K | −$11.4K | −$11.4K | −$3.3K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.3M | $708 | $1.7M | $99.6K | $5.9M | $9.0M | $5.9M | $422.1K |
| Operating income | −$5.8M | −$3.4K | −$4.2M | −$2.3M | −$11.9M | −$15.5M | −$11.8M | −$4.4M |
| EBITDA | −$5.8M | $0 | −$430.4K | $69.6M | −$11.9M | −$15.5M | −$11.8M | −$3.6M |
| Net income | −$6.7M | −$5.1K | −$5.4M | −$2.9M | −$11.9M | −$16.5M | −$12.2M | −$2.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -5.70 | -329.90 | -4.90 | -5.90 | -8.10 | -8.40 | -3.20 | -26.30 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $133M | $45.20 | $45.20–$45.20 | 1 |
| 2027 | $179M | $68.80 | $68.80–$68.80 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds NLSP.
No tracked institution reports a position in NLSP as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-10-31 | 1-for-10reverse |
| 2024-09-27 | 1-for-40reverse |
No one on the platform has traded NLSP yet.
| $13259 |
| — |
| KTTAPasithea Therapeutics Corp. | $0.53 | -3.18% | $4M | — |
| NUWENuwellis, Inc. | $3.18 | -3.64% | $1M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.